FULGENT GENETICS, INC. (FLGT) Gross Margin
- Gross margin · 12 months: Value 35.58%; Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | 35.58% | Gross profit / revenue. Period ending 2026-06-30. $115.26M ÷ $323.93M × 100 ≈ 35.58% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | 115.26M USD | Gross Profit |
| Revenue | 323.93M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | $115.26M | $323.93M | (m) | 35.58% |
| 2026-03-31 | $124.02M | $320.35M | (m) | 38.71% |
| 2025-12-31 | $130.88M | $322.67M | (m) | 40.56% |
| 2025-09-30 | $130.14M | $315.55M | (m) | 41.24% |
| 2025-06-30 | $121.40M | $303.22M | (m) | 40.04% |
| 2025-03-31 | $113.46M | $292.45M | (m) | 38.80% |
| 2024-12-31 | $107.22M | $283.47M | (m) | 37.82% |
| 2024-09-30 | $100.59M | $277.76M | (m) | 36.22% |
| 2024-06-30 | $113.67M | $290.70M | (m) | 39.10% |
| 2024-03-31 | $107.75M | $287.53M | (m) | 37.47% |
| 2023-12-31 | $104.46M | $289.21M | (m) | 36.12% |
| 2023-09-30 | $92.21M | $286.41M | (m) | 32.20% |
| 2023-06-30 | $98.47M | $307.38M | (m) | 32.03% |
| 2023-03-31 | $143.17M | $364.87M | (m) | 39.24% |
| 2022-12-31 | $366.90M | $618.97M | (m) | 59.28% |
| 2022-09-30 | $543.45M | $802.93M | (m) | 67.68% |
| 2022-06-30 | $681.76M | $925.15M | (m) | 73.69% |
| 2022-03-31 | $734.24M | $953.42M | (m) | 77.01% |
| 2021-12-31 | $777.05M | $992.58M | (m) | 78.29% |
| 2021-09-30 | $830.72M | $1.04B | (m) | 80.19% |
| 2021-06-30 | $721.77M | $909.74M | (m) | 79.34% |
| 2021-03-31 | $613.56M | $773.39M | (m) | 79.33% |
| 2020-12-31 | $331.90M | $421.71M | (m) | 78.70% |
| 2020-09-30 | $93.45M | $135.12M | (m) | 69.16% |
| 2020-06-30 | $24.46M | $43.75M | (m) | 55.90% |
| 2020-03-31 | $19.71M | $34.91M | (m) | 56.47% |
| 2019-12-31 | $18.42M | $32.53M | $0.00 | 56.63% |
| 2019-09-30 | $16.57M | $29.81M | (m) | 55.58% |
| 2019-06-30 | $13.12M | $25.09M | (m) | 52.30% |
| 2019-03-31 | $11.18M | $22.07M | (m) | 50.64% |
| 2018-12-31 | $10.65M | $21.35M | $0.00 | 49.90% |
| 2018-09-30 | $9.49M | $19.96M | (m) | 47.53% |
| 2018-06-30 | $8.71M | $18.84M | (m) | 46.23% |
| 2018-03-31 | $8.61M | $18.08M | (m) | 47.65% |
| 2017-12-31 | $10.18M | $18.73M | (m) | 54.35% |
| 2017-09-30 | $12.43M | $20.30M | (m) | 61.24% |
| 2017-06-30 | $13.07M | $20.81M | (m) | 62.78% |
| 2017-03-31 | $12.87M | $20.14M | (m) | 63.87% |
| 2016-12-31 | $11.55M | $18.28M | (m) | 63.22% |
| 2016-09-30 | (m) | (m) | (m) | (m) |
| 2016-06-30 | $6.86M | $13.22M | (m) | 51.89% |
| 2016-03-31 | $5.71M | $11.43M | (m) | 49.95% |
| 2015-12-31 | $4.51M | $9.58M | (m) | 47.07% |
| 2015-09-30 | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | (m) | (m) |
| 2014-12-31 | $342.00K | $1.28M | (m) | 26.76% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B |